Mirati team demonstrates that their KRAS G12C drug is active in NSCLC — but how do they stack up next to Amgen?

John Carroll

Editor & Founder

We have ourselves a horse race to watch in KRAS G12C, but it’s going to be awfully hard to call at this very early stage of the competition.

Mirati — $MRTX led by CEO Chuck Baum — came through with an encouraging set of responses to review for MRTX849 — particularly among a group of 6 evaluable patients suffering from non-small cell lung cancer who had received a dose of 600 mg twice daily, which is the high dose they plan to take forward as most likely to get a response with the least amount of potential harm to the patient.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Mirati team demonstrates that their KRAS G12C drug is active in NSCLC — but how do they stack up next to Amgen?

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

Cash, chips and talent: Inside Nvidia's plan to dominate biotech's AI revolution

Regeneron enters venture investing with $500M, poaches senior partner from ARCH

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

A majority of pharma and biotech companies prohibit ChatGPT use, survey finds

GSK unveils long-term Shingrix data as shingles competition heats up

Senate bill targeting WuXi won't affect federal spending, CBO says

Mi­rati team demon­strates that their KRAS G12C drug is ac­tive in NSCLC — but how do they stack up next to Am­gen?

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

more like this

Cash, chips and tal­ent: In­side Nvidi­a's plan to dom­i­nate biotech's AI rev­o­lu­tion

Re­gen­eron en­ters ven­ture in­vest­ing with $500M, poach­es se­nior part­ner from ARCH

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

A ma­jor­i­ty of phar­ma and biotech com­pa­nies pro­hib­it Chat­G­PT use, sur­vey finds

GSK un­veils long-term Shin­grix da­ta as shin­gles com­pe­ti­tion heats up

Sen­ate bill tar­get­ing WuXi won't af­fect fed­er­al spend­ing, CBO says

Mirati team demonstrates that their KRAS G12C drug is active in NSCLC — but how do they stack up next to Amgen?

Cash, chips and talent: Inside Nvidia's plan to dominate biotech's AI revolution

Regeneron enters venture investing with $500M, poaches senior partner from ARCH

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

A majority of pharma and biotech companies prohibit ChatGPT use, survey finds

GSK unveils long-term Shingrix data as shingles competition heats up

Senate bill targeting WuXi won't affect federal spending, CBO says